![]() Patients in Austria, Northern Ireland, Denmark and Germany will have access to the expanded indication for Kaftrio following the European Commission’s regulatory approval, and it has also been approved for use in New Zealand and Switzerland, where it is known as Trikafta. To be eligible patients must also have a f508del mutation. “As a physician, I welcome the approval of this medicine for this younger age group, as it will help us treat eligible children with CF as early as six years old.” Mall, Head of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at Charité University Medical Center Berlin. “CF is a progressive disease, in which symptoms and organ damage manifest very early in life,” said Professor Marcus A. The combination of ivacaftor, tezacaftor and elexacaftor has shown good results in people aged 12 and above with CF, and it is hoped the treatment will help slow down the advancement of the disease in younger patients. The European Commission has granted Vertex approval for the label extension of Kaftrio to treat cystic fibrosis (CF) in patients aged six to 11 years. Treatment for children with cystic fibrosis approved in Europe ![]() In the meantime a high-profile publicity campaign featuring Hollywood actress Jennifer Aniston is already underway. ![]() The FDA has recommended that Quviviq be classified as a controlled substance and it is expected to be available to patients from May 2022. “Daridorexant properties include a potent inhibition of both orexin receptors, a rapid absorption for sleep onset, and a pharmacokinetic profile such that around 80 percent of daridorexant has been eliminated after a night of sleep to help minimize residual effects.” Martine Clozel, MD and Chief Scientific Officer of Idorsia, explained: “After more than 20 years of research and a progressive understanding of the role of orexin in sleep-wake balance and of the potential of orexin receptor antagonism, we designed daridorexant to help address several issues people with insomnia face. The FDA’s approval signifies an important milestone for Idorsia and its husband and wife leadership team, who have been working on the insomnia pill for more than two decades. Swiss biotech firm Idorsia has received approval from the US Food and Drug Administration (FDA) for its insomnia drug Quviviq. New drug to treat insomnia approved by FDA The transplant follows announcements from Bayer and Pfizer in December 2021 on their new partnerships with Mammoth Biosciences and Beam Therapeutics respectively, two gene editing companies. So far the operation has been deemed a success. Revivicor made 10 alterations to the pig's genes, including inserting six human genes into its genome to prevent rejection of the organ once transplanted. ![]() Instead he consented to the transplant of a heart from a genetically modified pig created by Revivicor, a subsidiary of United Therapeutics. David Bennett, 57, underwent the seven-hour operation at the University of Maryland Medical Center in Baltimore, US.īennett had not been eligible for a human heart because he had advanced health problems. World’s first genetically-modified pig’s heart transplant is a successĪ US man has become the world's first person to receive a heart transplant from a genetically-modified pig thanks to advances in gene editing tools.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |